Cancer Immunotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cancer immunotherapy encompasses a broad and rapidly evolving set of treatments that harness or enhance the patient's own immune system to recognise, target, and destroy cancer cells. Unlike cytotoxic chemotherapy (which directly kills proliferating cells, malignant and normal alike) or targeted therapies (which inhibit specific oncogenic molecular drivers), immunotherapy operates by modulating the tumour-immune system interaction — either removing the immunosuppressive brakes that cancers impose on the immune system, or arming immune effector cells with the specificity to kill tumour cells directly.

The modern era of cancer immunotherapy was inaugurated by the clinical development of ipilimumab (Yervoy) — the first immune checkpoint inhibitor (anti-CTLA-4) — which received FDA approval in March 2011 for unresectable or metastatic melanoma. For the first time, a meaningful fraction of patients with stage IV melanoma (historically a disease with median survival of 8–9 months) achieved durable long-term remissions, with 10-year overall survival rates of approximately 20% reported in follow-up analyses of the early ipilimumab trials. These results were unprecedented in the history of systemic oncology and catalysed the transformation of oncological practice across virtually every solid tumour type and many haematological malignancies.

The principal classes of approved cancer immunotherapy agents are:

• Immune Checkpoint Inhibitors (ICI): Monoclonal antibodies targeting inhibitory immune checkpoints — PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1), and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) — that are exploited by tumour cells to escape immune surveillance. Blocking these checkpoints restores the capacity of cytotoxic T lymphocytes (CTL) to recognise and kill tumour cells.
• CAR-T Cell Therapy (Chimeric Antigen Receptor T-cell therapy): A personalised cellular therapy in which the patient's own T lymphocytes are genetically engineered ex vivo to express a chimeric antigen receptor (CAR) targeting a tumour-specific antigen, then expanded and reinfused to seek and destroy antigen-expressing tumour cells.
• Cancer Vaccines: Therapeutic vaccines designed to prime or boost an anti-tumour immune response — including sipuleucel-T (dendritic cell vaccine for prostate cancer) and personalised mRNA neoantigen vaccines (under active clinical development in melanoma and other tumour types).
• Bispecific Antibodies: Engineered antibodies that simultaneously bind to a tumour antigen and a T-cell activating receptor (CD3), physically recruiting T cells to the tumour cell surface to trigger tumour lysis — e.g., blinatumomab (CD19xCD3 for B-cell ALL), teclistamab (BCMAxCD3 for multiple myeloma).

The indications for immunotherapy have expanded dramatically since 2011. Checkpoint inhibitors are now approved by the FDA and/or EMA for more than 20 distinct oncological indications, and CAR-T and bispecific antibody therapy have transformed the treatment of several haematological malignancies. Key approved indications include:

Checkpoint Inhibitor-Approved Solid Tumours:

• Melanoma: The original indication and the benchmark for immunotherapy success. Combination ipilimumab plus nivolumab (CheckMate 067) produces 5-year overall survival of 52% in previously untreated advanced melanoma — transforming a disease with formerly median survival under 1 year. Pembrolizumab (KEYNOTE-006) achieves 5-year OS of 43% vs 31% for ipilimumab.
• Non-Small Cell Lung Cancer (NSCLC): Pembrolizumab monotherapy is first-line standard of care for tumours with PD-L1 TPS of 50% or higher (KEYNOTE-024: HR 0.62 for progression-free survival). Pembrolizumab plus chemotherapy is indicated for all NSCLC without driver mutations regardless of PD-L1 level (KEYNOTE-189 for non-squamous, KEYNOTE-407 for squamous). Atezolizumab, durvalumab, and cemiplimab have additional NSCLC approvals.
• Renal Cell Carcinoma (RCC): Nivolumab plus ipilimumab (CheckMate 214) and pembrolizumab plus axitinib (KEYNOTE-426) are first-line standards for advanced clear cell RCC, replacing sunitinib monotherapy. Response rates of 40–60% and durable complete remissions are observed.
• Urothelial and Bladder Cancer: Pembrolizumab second-line for platinum-refractory disease (KEYNOTE-045); atezolizumab, pembrolizumab, nivolumab, and durvalumab as maintenance or first-line options in cisplatin-ineligible patients.
• Head and Neck Squamous Cell Carcinoma (HNSCC): Pembrolizumab monotherapy (CPS of 1 or higher) or in combination with chemotherapy (KEYNOTE-048) for first-line recurrent/metastatic disease.
• Microsatellite Instability-High (MSI-H) / Mismatch Repair-Deficient (dMMR) Tumours (Pan-Tumour Approval): Pembrolizumab was the first tumour-agnostic FDA approval (2017) for any previously treated solid tumour with MSI-H/dMMR regardless of histological type, based on KEYNOTE-158. This includes colorectal cancer (most common MSI-H tumour), endometrial cancer, gastric cancer, biliary tract cancer, and others. High TMB (greater than 10 mutations per megabase) is a pan-tumour approval for pembrolizumab (KEYNOTE-158).
• Hepatocellular Carcinoma (HCC), Cervical Cancer, Merkel Cell Carcinoma, Small Cell Lung Cancer (SCLC), Oesophageal Cancer, and Gastric/GEJ Cancer all have approved checkpoint inhibitor indications.

CAR-T Cell Therapy-Approved Indications:

• Tisagenlecleucel (Kymriah): relapsed/refractory B-cell ALL in patients 25 years old and younger; relapsed/refractory DLBCL after 2 or more prior therapies
• Axicabtagene ciloleucel (Yescarta): relapsed/refractory DLBCL, follicular lymphoma grade 3B, primary mediastinal large B-cell lymphoma; and second-line DLBCL (ZUMA-7 trial)
• Lisocabtagene maraleucel (Breyanzi): relapsed/refractory DLBCL and indolent B-cell lymphomas; second-line LBCL (TRANSFORM trial)
• Ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (Abecma): relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including BCMA-targeting bispecific

Eligibility for immunotherapy depends on the specific agent and indication, but several key biological and clinical factors are universally relevant to checkpoint inhibitor selection and patient selection for CAR-T cell therapy.

Predictive Biomarkers for Checkpoint Inhibitors:

• PD-L1 Expression (TPS and CPS): Tumour Proportion Score (TPS) measures PD-L1 expression on tumour cells only (relevant for NSCLC pembrolizumab monotherapy threshold: TPS 50% or higher for first-line monotherapy; TPS 1% or higher for second-line). Combined Positive Score (CPS) counts PD-L1-positive tumour cells, macrophages, and lymphocytes divided by total viable tumour cells, multiplied by 100 (relevant for HNSCC and gastric cancer: CPS 10 or higher for pembrolizumab benefit). PD-L1 testing is performed on tumour tissue by IHC using validated companion diagnostics (22C3 pharmDx for pembrolizumab, SP142 for atezolizumab — assays are not interchangeable).
• Microsatellite Instability (MSI-H) and Mismatch Repair Deficiency (dMMR): MSI-H/dMMR predicts exceptional sensitivity to checkpoint inhibition across tumour histotypes. Testing by IHC for MLH1, MSH2, MSH6, PMS2 (loss of nuclear expression indicates dMMR), or PCR/NGS for microsatellite instability, is mandatory for colorectal and endometrial cancer and recommended for all solid tumours at initial diagnosis per NCCN guidelines 2024.
• Tumour Mutational Burden (TMB): High TMB (10 or more mutations per megabase by comprehensive genomic profiling) is associated with higher neoantigen load and greater immunotherapy sensitivity. FDA-approved as a pan-tumour biomarker for pembrolizumab (KEYNOTE-158). TMB assessment requires comprehensive NGS panel (Foundation One CDx, MSK-IMPACT, or equivalent).

General Clinical Eligibility (Checkpoint Inhibitors):

• ECOG Performance Status 0–2 (some trials included PS 3 patients with short-term improvement potential)
• No active autoimmune disease requiring systemic immunosuppression (relative contraindication; emerging data from expanded access suggests some autoimmune patients can be treated with careful monitoring)
• No prior solid organ transplant (high risk of rejection from immune activation)
• Adequate organ function: creatinine clearance above 30 ml/minute, liver function tests below 3x ULN (upper limit of normal), haematological reserve

CAR-T Cell Therapy Eligibility: Relapsed or refractory disease after 2 or more prior lines of therapy (specific number depends on the product and indication); adequate cardiac function (LVEF above 50%); absence of active CNS lymphoma for most CD19-targeting CAR-T products (exception: some DLBCL protocols permit treatment of parenchymal CNS disease); no active severe infection; adequate marrow reserve or ability to tolerate lymphodepleting chemotherapy (cyclophosphamide/fludarabine); ability to travel to and stay near a certified CAR-T centre for the required observation period post-infusion.

The immunotherapy treatment landscape is large and rapidly evolving. The following are the major approved agents and their key clinical applications:

PD-1 Checkpoint Inhibitors:

• Pembrolizumab (Keytruda, Merck/MSD): An anti-PD-1 humanised IgG4 monoclonal antibody. Administered IV every 3 weeks (200 mg) or every 6 weeks (400 mg flat dose). The broadest oncology approval of any checkpoint inhibitor — more than 40 FDA-approved indications spanning melanoma, NSCLC, HNSCC, bladder, gastric, colorectal (MSI-H), endometrial, cervical, HCC, biliary tract, oesophageal, TMB-H pan-tumour, and others. Both as monotherapy and in combination with chemotherapy, targeted therapy, or other immunotherapy agents.
• Nivolumab (Opdivo, Bristol-Myers Squibb): An anti-PD-1 fully human IgG4 monoclonal antibody. Administered IV every 2 weeks (3 mg/kg) or every 4 weeks (480 mg flat dose). Approved for melanoma, NSCLC, SCLC, RCC, Hodgkin lymphoma, HNSCC, urothelial carcinoma, colorectal cancer (MSI-H), HCC, oesophageal cancer, and gastric/GEJ cancer — typically as part of dual ICI combinations with ipilimumab or in combination with chemotherapy.

PD-L1 Checkpoint Inhibitors:

• Atezolizumab (Tecentriq, Genentech/Roche): An anti-PD-L1 IgG1 monoclonal antibody. Approved for NSCLC (first-line with bevacizumab/chemotherapy and as monotherapy for high PD-L1 expression), SCLC, urothelial carcinoma, hepatocellular carcinoma, and triple-negative breast cancer (PD-L1-positive).
• Durvalumab (Imfinzi, AstraZeneca): Anti-PD-L1 antibody approved for unresectable stage III NSCLC after concurrent chemoradiotherapy (PACIFIC trial: 5-year OS 42% vs 33% with placebo; a landmark result) and in combination with chemotherapy for extensive-stage SCLC and biliary tract cancer (TOPAZ-1 trial).

CTLA-4 Checkpoint Inhibitor:

• Ipilimumab (Yervoy, Bristol-Myers Squibb): An anti-CTLA-4 human IgG1 monoclonal antibody. The first checkpoint inhibitor approved (FDA 2011, melanoma). Produces deeper and more durable responses when combined with nivolumab (CheckMate 067, 067-LBA) than either agent alone, at the cost of substantially higher immune-related toxicity (grade 3–4 irAEs in 55% of combination-treated patients vs 20% for nivolumab monotherapy). Also approved for NSCLC, RCC, and HCC (combination with nivolumab), and for hepatocellular carcinoma. Low-dose ipilimumab (1 mg/kg every 6 weeks) combined with nivolumab is the standard combination regimen, reducing toxicity compared with the original 3 mg/kg dose.

CAR-T Cell Therapy — Manufacturing and Administration: The patient undergoes leukapheresis (collection of peripheral blood T lymphocytes). T cells are shipped to the manufacturer where they are genetically engineered by retroviral or lentiviral transduction to express the target CAR construct, then expanded to clinical scale over 2–4 weeks. The manufactured CAR-T cell product is cryopreserved and shipped back to the treating centre. The patient receives lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2 plus fludarabine 30 mg/m2 for 3 days) followed by a single IV infusion of the CAR-T product (target cell dose 0.6–6 x 10^8 CAR-T cells depending on the product). Patients are observed in-hospital for 7–14 days post-infusion for CRS and ICANS monitoring.

Cancer Vaccines: Sipuleucel-T (Provenge, Dendreon) is an autologous dendritic cell vaccine approved for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The patient undergoes 3 leukapheresis procedures; collected antigen-presenting cells are incubated with a fusion protein of PAP (prostatic acid phosphatase) and GM-CSF, then reinfused. Three infusions over approximately 4 weeks. The IMPACT trial demonstrated a 4.1-month improvement in median OS (25.8 vs 21.7 months, HR 0.78). Personalised mRNA neoantigen vaccines (Moderna/Merck mRNA-4157 plus pembrolizumab) demonstrated 44% reduction in recurrence or death in resected stage III/IV melanoma at 2-year follow-up (KEYNOTE-942 phase 2b) and are in phase 3 development.

Cancer immunotherapy has produced clinical outcomes that were previously unachievable with chemotherapy or targeted therapy in several major cancer types:

• Durable Long-Term Remissions and Potential Cure: A subset of patients treated with checkpoint inhibitors achieves durable complete responses lasting years after treatment discontinuation — a pattern of response virtually never observed with chemotherapy. The 10-year overall survival rate in ipilimumab-treated metastatic melanoma (approximately 20%) and the plateau on Kaplan-Meier OS curves in long-term follow-up data from CheckMate 067 (at approximately 50% surviving at 6.5 years) suggest that a fraction of patients achieve immune-mediated cancer control equivalent to functional cure.
• Efficacy Independent of Histology (for Biomarker-Selected Patients): The pan-tumour FDA approvals for pembrolizumab in MSI-H/dMMR and high-TMB tumours represent a paradigm shift in oncology: the first treatments selected on molecular characteristics of the tumour rather than its tissue of origin. This agnostic approach is particularly valuable for rare cancer histotypes where no histotype-specific therapy exists.
• Favourable Tolerability Profile vs Chemotherapy: Checkpoint inhibitors do not cause the direct cytotoxic effects of chemotherapy (nausea, vomiting, myelosuppression, alopecia, peripheral neuropathy, mucositis). Many patients receiving pembrolizumab or nivolumab report minimal impact on daily functioning and quality of life during treatment — a striking contrast to chemotherapy. CTLA-4 inhibition and combination ICI have higher toxicity profiles than PD-1/PD-L1 monotherapy.
• CAR-T Cell Therapy in Refractory Haematological Malignancies: CD19-targeting CAR-T therapies (tisagenlecleucel, axicabtagene ciloleucel) achieve complete remission rates of 40–54% in heavily pre-treated relapsed/refractory DLBCL — a patient population with a historical median OS of 6 months. Long-term follow-up shows durable CR in approximately 30–40% at 2 years (JULIET, ZUMA-1 trials). In paediatric and young adult relapsed/refractory ALL (ELIANA trial), complete remission rate was 81% with tisagenlecleucel, enabling subsequent haematopoietic stem cell transplantation in many patients.
• Improved Outcomes in Combination with Chemotherapy: Adding a checkpoint inhibitor to standard chemotherapy improves OS or PFS in multiple settings (pembrolizumab plus carboplatin/pemetrexed in non-squamous NSCLC — KEYNOTE-189 improved median OS from 11.3 to 22.0 months). These combinations have become the new standard of care for first-line treatment across multiple tumour types.

Immunotherapy carries a distinct toxicity profile compared with chemotherapy, characterised by immune-related adverse events (irAEs) — inflammatory side effects caused by non-specific immune activation in normal tissues. The severity ranges from manageable low-grade side effects to life-threatening emergencies.

Immune-Related Adverse Events (irAEs) — Checkpoint Inhibitors:

• Gastrointestinal (Colitis): The most common serious irAE with anti-CTLA-4 therapy. Grade 3–4 diarrhoea/colitis occurs in 8–12% of patients receiving ipilimumab monotherapy (3 mg/kg) and in 12–16% of patients receiving ipilimumab plus nivolumab combination therapy. Management: Grade 1 (mild diarrhoea) — continue treatment with monitoring; Grade 2 — hold immunotherapy, commence oral prednisone 1 mg/kg; Grade 3–4 — permanently discontinue ipilimumab, administer IV methylprednisolone 1–2 mg/kg, and if no improvement in 48–72 hours, add infliximab 5 mg/kg IV (anti-TNF, contraindicated if bowel perforation). Requires urgent colonoscopy for Grade 3 or higher to confirm immune colitis and exclude infection.
• Pulmonary (Pneumonitis): Checkpoint inhibitor-associated pneumonitis occurs in 2–5% of patients on PD-1/PD-L1 monotherapy and up to 10% on combination ICI. Presents with dyspnoea, dry cough, and new infiltrates on HRCT (typically ground-glass opacification). Grade 2 or higher: hold immunotherapy and start prednisone 1–2 mg/kg with slow taper over 4–6 weeks. Severe or steroid-refractory pneumonitis may require mycophenolate mofetil, rituximab, or cyclophosphamide. Fatal pneumonitis occurs in less than 1% of patients. Pneumonitis is more common in patients previously treated with thoracic radiotherapy.
• Hepatotoxicity: Immune-mediated hepatitis (elevated ALT/AST) occurs in 5–10% of patients on combination ICI. Grade 2: hold immunotherapy, initiate prednisone 0.5–1 mg/kg. Grade 3–4: high-dose IV methylprednisolone; if refractory after 48 hours, add mycophenolate mofetil 1 g twice daily. Azathioprine is contraindicated in ICI hepatitis.
• Endocrinopathies: Primary hypothyroidism (8–10% with PD-1 monotherapy; higher with combination) requires lifelong levothyroxine replacement. Hypophysitis (pituitary inflammation — more common with anti-CTLA-4, approximately 8%) causes hypopituitarism (hypogonadism, secondary hypothyroidism, secondary adrenal insufficiency); primary adrenal insufficiency requires lifelong hydrocortisone and fludrocortisone. Type 1 diabetes mellitus (new-onset) occurs rarely (less than 1%) but can present as fulminant diabetic ketoacidosis. Endocrine irAEs generally do not resolve and require lifelong hormone replacement — immunotherapy need not be permanently discontinued for endocrinopathies that are controlled with replacement therapy.
• Immune Checkpoint Inhibitor Myocarditis: A rare (less than 1%) but highly dangerous irAE. Mortality from confirmed ICI myocarditis is approximately 25–50% in published case series. Presents with new chest pain, dyspnoea, arrhythmia, or heart block. Diagnosis: cardiac MRI, troponin, ECG. Management: permanent ICI discontinuation, high-dose IV methylprednisolone (1 g daily), and often additional immunosuppression. Any suspicion should trigger urgent cardiology review.

CAR-T Cell Therapy Toxicities:

• Cytokine Release Syndrome (CRS): Results from massive immune activation and cytokine release following CAR-T expansion in vivo. Graded 1–4 (ASTCT 2019 consensus criteria). Fever is the cardinal symptom (grade 1). Hypotension (grade 2) and hypoxia (grade 2–3) indicate higher severity. Grade 3–4 CRS requires ICU-level care. Management: tocilizumab (IL-6 receptor antagonist, Actemra) 8 mg/kg IV is first-line for grade 2 or higher CRS; dexamethasone for steroid-responsive cases; siltuximab (anti-IL-6) as an alternative. Median onset of CRS is 2–3 days post-infusion.
• ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome): CNS toxicity characterised by confusion, aphasia, encephalopathy, seizures, and cerebral oedema. ICANS is graded 1–4 using the ICE (Immune Effector Cell-Associated Encephalopathy) score. Management: dexamethasone 10 mg IV every 6 hours (Grade 2–3); high-dose methylprednisolone and escalating immunosuppression for Grade 4. ICANS typically occurs 4–7 days post-infusion, after peak CRS.
• Prolonged Cytopenias and Infection: Lymphodepleting chemotherapy and CAR-T-mediated bone marrow suppression cause prolonged neutropenia, anaemia, and thrombocytopenia lasting weeks to months. G-CSF support, transfusions, and prophylactic antimicrobials are used. B-cell aplasia and hypogammaglobulinaemia (from on-target CD19 depletion) persist for months to years and require regular IVIG replacement therapy to prevent serious bacterial infections.

Patients receiving checkpoint inhibitors require structured monitoring for irAEs throughout the treatment course and for months to years after treatment completion, as irAEs can develop at any time — including after treatment discontinuation. CAR-T cell therapy requires intensive early monitoring followed by long-term surveillance for late effects.

Routine On-Treatment Monitoring — Checkpoint Inhibitors: Patients are reviewed every 2–3 weeks (at each infusion for pembrolizumab q3w or nivolumab q2w schedules). Each visit includes: symptom review (CTCAE grading of irAEs), full blood count, comprehensive metabolic panel (LFTs, creatinine, electrolytes), thyroid function tests (TSH, free T4) every 4–6 weeks, and glucose monitoring. Morning cortisol should be checked if hypophysitis or primary adrenal insufficiency is suspected. Chest radiograph or CT is performed as clinically indicated for any respiratory symptoms. Troponin and ECG should be checked at baseline and with any cardiovascular symptoms given the risk of ICI myocarditis.

Tumour Response Assessment: Imaging assessment of response is typically performed every 8–12 weeks using CT chest/abdomen/pelvis with contrast (or PET-CT for melanoma and lymphoma). Modified criteria including iRECIST (immune-related RECIST) are used to distinguish true disease progression from pseudoprogression — a phenomenon in which tumours appear to enlarge on initial imaging due to immune cell infiltration before subsequent regression. Pseudoprogression occurs in approximately 5–10% of melanoma and NSCLC patients responding to checkpoint inhibition.

Duration of Treatment: Pembrolizumab and nivolumab are typically continued until disease progression, unacceptable toxicity, or for a fixed period (24 months in KEYNOTE-024 for NSCLC with PD-L1 TPS of 50% or higher — patients completing 2 years of therapy retained benefit after discontinuation in approximately 70% of cases). The optimal duration of ICI therapy remains an active research question.

CAR-T Cell Therapy Post-Infusion Monitoring: Patients are monitored in-hospital for 7–14 days post-infusion. REMS (Risk Evaluation and Mitigation Strategy) programmes require patients to remain within 2 hours of a certified treatment centre for 4 weeks post-infusion. Outpatient monitoring thereafter: weekly CBC and comprehensive metabolic panel for the first month; monthly thereafter. IVIG replacement (0.4–0.5 g/kg IV every 3–4 weeks) is initiated when IgG falls below 400 mg/dL. Chimerism and CAR-T cell persistence are monitored by flow cytometry. Disease response is assessed by PET-CT at day 30 and day 90 post-infusion.

Long-Term Survivorship: Patients achieving durable remission with checkpoint inhibitors are followed indefinitely for late irAEs (thyroid dysfunction, adrenal insufficiency, and rarely pneumonitis can develop years after treatment cessation), standard cancer surveillance, and management of treatment-related endocrine replacement needs. Psychosocial support, return-to-work planning, and oncofertility counselling are components of comprehensive survivorship care.

Cancer immunotherapy represents some of the most expensive treatments in modern medicine. Understanding cost drivers is important for patients, clinicians, and health systems navigating access and affordability.

• Checkpoint Inhibitor Drug Cost: The monthly drug cost of pembrolizumab in the United States is approximately USD 15,000–20,000 per 3-week cycle (200 mg flat dose), translating to approximately USD 130,000–150,000 per year for continuous treatment. Nivolumab and atezolizumab have comparable costs. Annual per-patient drug expenditure for ICI-based regimens in the US ranges from USD 100,000 to over USD 200,000 for combination regimens. These costs are substantially lower in countries with national reference price frameworks (UK NICE appraisal, European HTA bodies) and in generics markets where biosimilars have entered.
• CAR-T Cell Therapy Manufacturing and Infusion Cost: The list price of approved CAR-T products in the US ranges from USD 350,000 (tisagenlecleucel for paediatric ALL) to USD 475,000 (axicabtagene ciloleucel for DLBCL) and up to USD 465,000 (ciltacabtagene autoleucel for multiple myeloma). These figures represent the product cost only and do not include hospitalisation for lymphodepletion and post-infusion monitoring (estimated at USD 50,000–100,000 additional), supportive care costs (tocilizumab for CRS management, IVIG for B-cell aplasia), and long-term follow-up. Total cost of care for a CAR-T cell therapy episode frequently exceeds USD 600,000.
• Biomarker Testing Cost: PD-L1 IHC testing adds USD 100–400 per tumour sample. Comprehensive genomic profiling (Foundation One CDx, GUARDANT360 liquid biopsy) for TMB, MSI, and fusion gene analysis adds USD 3,000–6,000, though insurance coverage is increasingly available when the test is tied to a companion diagnostic for an approved drug indication.
• Outpatient Administration Infrastructure: Checkpoint inhibitors are administered IV in infusion centres, typically over 30–60 minutes every 3–6 weeks. The infusion chair time, pharmacy preparation, and nursing administration costs add USD 500–2,000 per infusion in the US outpatient hospital setting.
• Country and Access Variation: The UK NHS has negotiated confidential rebates with manufacturers and funds pembrolizumab and nivolumab for approved indications via NICE technology appraisals. In India, pembrolizumab costs approximately INR 170,000–200,000 per 200 mg dose — substantially lower than the US list price but still a significant burden without insurance coverage. Financial toxicity is a recognised adverse effect of immunotherapy affecting patient adherence and quality of life.

Immunotherapy does not replace all other cancer treatments. For most tumour types, it is used in combination with or in sequence after other modalities, and selecting the optimal approach requires understanding the strengths and limitations of each:

• Cytotoxic Chemotherapy: Remains the backbone of treatment for many cancers, either as monotherapy or in combination with checkpoint inhibitors. For patients whose tumours lack predictive biomarkers for immunotherapy benefit (PD-L1-negative NSCLC without driver mutations, low TMB, microsatellite stable colorectal cancer), first-line platinum-based chemotherapy remains the standard. Even in biomarker-positive tumours, chemoimmunotherapy combinations (pembrolizumab plus carboplatin/paclitaxel/nab-paclitaxel for triple-negative breast cancer — KEYNOTE-522; pembrolizumab plus carboplatin/pemetrexed for non-squamous NSCLC — KEYNOTE-189) outperform immunotherapy monotherapy for OS in unselected populations.
• Targeted Therapy (Small Molecule Kinase Inhibitors): For oncogene-driven tumours — EGFR-mutant NSCLC (osimertinib), ALK-rearranged NSCLC (alectinib, brigatinib), BRAF V600E-mutant melanoma (dabrafenib plus trametinib), HER2-positive breast cancer (trastuzumab deruxtecan) — targeted therapy remains the preferred first-line treatment due to superior PFS and response rates compared with immunotherapy in these biomarker-defined populations. Checkpoint inhibitors are generally used later in the treatment sequence for these patients, after targeted therapy progression or resistance.
• Radiation Therapy with Immunotherapy (Radioimmunotherapy): Radiation therapy may enhance the immunological effects of checkpoint inhibitors through the abscopal effect — immune activation at non-irradiated tumour sites triggered by radiation-induced tumour antigen release and danger signalling. The combination of SBRT with checkpoint inhibitors is under active investigation across multiple tumour sites. Durvalumab consolidation after concurrent chemoradiotherapy for unresectable stage III NSCLC (PACIFIC trial) is the best-validated example of combined radioimmunotherapy, improving median OS from 28.7 months (placebo) to not reached at 5-year analysis.
• Antibody-Drug Conjugates (ADCs): Engineered antibodies linked to cytotoxic payloads (e.g., trastuzumab deruxtecan for HER2-low breast cancer; sacituzumab govitecan for triple-negative breast cancer; enfortumab vedotin for urothelial cancer) deliver targeted chemotherapy to tumour cells expressing the cognate antigen. ADCs are increasingly used sequentially or concurrently with checkpoint inhibitors — the enfortumab vedotin plus pembrolizumab combination (EV-302/KEYNOTE-A39) produced unprecedented PFS and OS in metastatic urothelial cancer and is a first-line standard of care.
• Bispecific T-Cell Engagers and NK-Cell Engagers: Bispecific antibodies (blinatumomab CD19xCD3 for ALL; teclistamab BCMAxCD3 for myeloma; mosunetuzumab CD20xCD3 for follicular lymphoma; epcoritamab CD20xCD3 for DLBCL) are increasingly replacing CAR-T cell therapy or preceding it in the treatment sequence for haematological malignancies, offering a simpler off-the-shelf administration without the manufacturing delays and logistical complexity of CAR-T.